Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2976 of 5804
-
Could a common ED drug ease cystic fibrosis lung inflammation?
Disease control CompletedThe purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.
Phase: PHASE1, PHASE2 • Sponsor: National Jewish Health • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can low blood flow predict stroke? new study investigates
Knowledge-focused CompletedPatients with blockage of the blood vessels that supply blood to the back of the brain, known as vertebrobasilar disease (VBD), are at risk of having a stroke or temporary symptoms of a stroke known as transient ischemic attack (TIA). The risk of repeated stroke associated with V…
Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Could a common antifungal keep Crohn's away after surgery?
Disease control CompletedThis was prospective study randomized in two controlled parallel groups verum versus placebo. The objectives were to assess the influence of antifungal treatment with Fluconazole (FCZ) on the rate of ASCA and endoscopic recurrence at 6 months. The rational was based on our previo…
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
MRI dye may shield cancer patients from nerve pain
Symptom relief CompletedOxaliplatin is a major antitumor agent but its use is limited by potentially disabling neurotoxicity, characterized by a sensitive defect in the extremities.Mangafodipir is a MRI contrast agent with antioxidant properties. Our previous laboratory works showed that mangafodipir is…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Could a natural hormone help COPD patients breathe easier?
Disease control CompletedDHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in human. The purpose of this study is to determine if DHEA is effective in the treatment of respiratory pulmonary …
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail tested for tough pancreatic cancer
Disease control CompletedRATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes neede…
Phase: PHASE1 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise for rare lung condition in early trial
Disease control CompletedThis is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study. Eligible subjects will undergo an open-label, single-dose acute hemodynamic study with ACT-293987(NS-304) and 21 …
Phase: PHASE2 • Sponsor: Actelion • Aim: Disease control
Last updated Jun 26, 2026 15:53 UTC
-
Massive genetic study aims to unlock secrets of rare metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONInborn Errors of metabolism comprise a large number of rare conditions with a collective incidence of around 1/2000 newborns. Many disorders are treatable provided that a correct diagnosis can be established in time, and for many diseases novel therapies are being developed. With…
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New schizophrenia drug shows promise in early trial
Disease control CompletedThe purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fi…
Phase: PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Personalized rehab shows promise for rare muscle diseases
Symptom relief CompletedThe purpose of this study is to evaluate the efficacy of an active rehabilitation program on disability and quality of life of patients affected by dermatomyositis and polymyositis.
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Heart MRI shows promise as a 'Silver Standard' for diagnosing rare cardiac masses
Diagnosis ENROLLING_BY_INVITATIONThe goal of this observational study is to explore the diagnostic accuracy, treatment-guiding value, and prognostic predictive utility of cardiovascular magnetic resonance (CMR) in patients with suspected or confirmed cardiac masses. Cardiac masses include neoplastic (primary tum…
Sponsor: Minjie Lu • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
New diabetes pill shows promise in early trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration once dai…
Phase: PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Scientists decode genetic secrets of liver cancer in 808 patients
Knowledge-focused CompletedThe MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of circulating tumor DNA.
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Brain radiation for breast cancer: prevention study halted early
Prevention TerminatedEvaluate the survival without metastasis in patients treated by Trastuzumab in association with other chemotherapies for a breast cancer expressing HER2-NEU.
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
COPDGene: unlocking the genetic secrets of lung disease in smokers
Knowledge-focused OngoingChronic obstructive pulmonary disease (COPD) is a long-term lung disease that is often caused by cigarette smoking. The purpose of this study is to evaluate whether certain genetic factors predispose some smokers to develop COPD more than others.
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:03 UTC
-
Phone coaching gets cancer survivors off the couch
Symptom relief OngoingThis study is being done to determine whether a telephone-based counseling intervention can help survivors of breast and colorectal cancer increase their weekly physical activity. Observational evidence suggests that physical activity after breast and colorectal cancer diagnosis …
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Blood test could spot Parkinson's earlier, study hopes
Knowledge-focused CompletedThe main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to determine gene expression profiles specific for genetic and idiopathic Parkinson's disease (PD) patients. These gene expression signatures will be utilised clinically as non-invasive diagn…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New hope for dialysis patients: drug targets dangerous phosphate levels
Disease control CompletedThis is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Lung cancer drug combo fails to extend survival in major trial
Disease control CompletedThe primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectiv…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
New hope for depressed smokers: therapy plus quit support shows promise
Disease control OngoingObjectives: Primary Aim: To conduct a preliminary randomized trial in smokers with current recurrent major depressive disorder (MDD), current MDD with a single episode of 2 years or more, and current dysthymia comparing combined cognitive behavioral analysis system of psychothe…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC